Literature DB >> 22189998

GH response to GHRH plus arginine is impaired in lipoatrophic women with human immunodeficiency virus compared with controls.

Lucia Zirilli1, Gabriella Orlando, Federica Carli, Bruno Madeo, Stefania Cocchi, Chiara Diazzi, Cesare Carani, Giovanni Guaraldi, Vincenzo Rochira.   

Abstract

OBJECTIVE: GH secretion is impaired in lipodystrophic human immunodeficiency virus (HIV) patients and inversely related to lipodystrophy-related fat redistribution in men. Less is known about the underlying mechanisms involved in reduced GH secretion in HIV-infected women.
DESIGN: A case-control, cross-sectional study comparing GH/IGF1 status, body composition, and metabolic parameters in 92 nonobese women with HIV-related lipodystrophy and 63 healthy controls matched for age, ethnicity, sex, and body mass index (BMI).
METHODS: GH, IGF1, IGF binding protein 3 (IGFBP3), GH after GHRH plus arginine (GHRH+Arg), several metabolic variables, and body composition were evaluated.
RESULTS: GH response to GHRH+Arg was lower in HIV-infected females than in controls. Using a cutoff of peak GH ≤ 7.5 μg/l, 20.6% of HIV-infected females demonstrated reduced peak GH response after GHRH+Arg. In contrast, none of the control subjects demonstrated a peak GH response ≤ 7.5 μg/l. Bone mineral density (BMD), quality of life, IGF1, and IGFBP3 were lowest in the HIV-infected females with a GH peak ≤ 7.5 μg/l. BMI was the main predictive factor of GH peak in stepwise multiregression analysis followed by age, with a less significant effect of visceral fat in the HIV-infected females.
CONCLUSIONS: This study establishes that i) GH response to GHRH+Arg is lower in lipoatrophic HIV-infected women than in healthy matched controls, ii) BMI more than visceral adipose tissue or trunk fat influences GH peak in this population, and iii) HIV-infected women with a GH peak below or equal to 7.5 μg/l demonstrate reduced IGF1, IGFBP3, BMD, and quality of life.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22189998     DOI: 10.1530/EJE-11-0829

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

1.  Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.

Authors:  Mario González-Sales; Olivier Barrière; Pierre Olivier Tremblay; Fahima Nekka; Jean-Claude Mamputu; Sylvie Boudreault; Mario Tanguay
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-04-21       Impact factor: 2.745

2.  Pituitary growth hormone (GH) secretion is partially rescued in HIV-infected patients with GH deficiency (GHD) compared to hypopituitary patients.

Authors:  Chiara Diazzi; Giulia Brigante; Giulia Ferrannini; Anna Ansaloni; Lucia Zirilli; Maria Cristina De Santis; Stefano Zona; Giovanni Guaraldi; Vincenzo Rochira
Journal:  Endocrine       Date:  2016-10-11       Impact factor: 3.633

3.  Serum total estradiol, but not testosterone is associated with reduced bone mineral density (BMD) in HIV-infected men: a cross-sectional, observational study.

Authors:  D Santi; B Madeo; F Carli; S Zona; G Brigante; F Vescini; G Guaraldi; V Rochira
Journal:  Osteoporos Int       Date:  2015-10-28       Impact factor: 4.507

4.  Insulin-like growth factor 1 inversely relates to monocyte/macrophage activation markers in HIV.

Authors:  Lindsay T Fourman; Natalia Czerwonka; Sofia D Shaikh; Takara L Stanley; Tricia H Burdo; Kenneth C Williams; Kathleen V Fitch; Janet Lo; Steven K Grinspoon
Journal:  AIDS       Date:  2018-04-24       Impact factor: 4.177

Review 5.  Male sexual dysfunction and HIV--a clinical perspective.

Authors:  Daniele Santi; Giulia Brigante; Stefano Zona; Giovanni Guaraldi; Vincenzo Rochira
Journal:  Nat Rev Urol       Date:  2014-01-07       Impact factor: 14.432

6.  In vitro and in vivo effects of IGF-I on adiposity in HIV-associated metabolic disease: a pilot study.

Authors:  Roy J Kim; Sumit Vaghani; Larisa M Zifchak; Joseph H Quinn; Weimian He; Pablo Tebas; Ian Frank
Journal:  Arch Med Res       Date:  2013-07-16       Impact factor: 2.235

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.